000			05406nam a22003975i 4500
999			_c11069 _d11069
001			11069
003			DE-He213
005			20210629040337.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			180511s2018 si | s |||| 0|eng d
020			_a9789811070136
024	7		_a10.1007/978-981-10-7013-6 _2doi
040			_bspa _dES-MaUEC
050		4	_aRC280 _b.H67 2018 EB
245	0	0	_aHormone Therapy and Castration Resistance of Prostate Cancer _cedited by Yoichi Arai, Osamu Ogawa.
264		1	_aSingapore _bSpringer Singapore : _bImprint: Springer _c2018.
300			_a1 recurso en línea ( VIII, 433 páginas, 65 ilustraciones, 34 ilustraciones a color)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF _2rda
490	0		_aMedicine (Springer-11650)
505	0		_a1. Introduction -- 2. Recent trends in hormone therapy for prostate cancer in Japan -- 3. Risk assessment among patients receiving primary ADT -- 4. Patient-derived xenografts for research on hormonal therapy of prostate cancer -- 5. Impact of GnRH antagonist and LHRH agonist on the gonadal axis -- 6. Controversies on complete androgen blockade -- 7. Adrenal androgen in prostate cancer -- 8. Intermittent ADT for prostate cancer -- 9. Pognostic significance of monitoring serum testosterone in primary ADT -- 10. Ethnic variation in clinical outcomes of primary ADT for prostate cancer -- 11. ADT in combination with radical prostatectomy -- 12. ADT in combination with radiation therapy -- 13. ADT as salvage therapy after definitive treatment -- 14. ADT for clinically localised prostate cancer -- 15. Complications of ADT -- 16. Hot flash -- 17. Oseteoporosis and fracture risk -- 18. Metaboplic change -- 19. Bone scan index as a biomarker of bone metastasis -- 20. Genetic polymorphism analysis in predicting prognosis of metastatic prostate cancer -- 21. Local therapy in combination with ADT for metastatic prostate cancer -- 22. Oxidative stress and CRPC -- 23. Alternative antiandrogen therapy for CRPC -- 24. Optimization of sequential AR targeted therapy for CRPC -- 25. Enzalutamide therapy for mCRPC in Japanese men -- 26. Abiraterone acetate therapy for mCRPC in Japanese men -- 27. Role of estramustine phosphate for CRPC -- 28. Steroid therapy for CRPC -- 29. MicroRNA analysis in prostate cancer -- 30. AR splicing variant in prostate cancer -- 31. Detection of CTC in CRPC -- 32. New biomarker for CRPC: Glycobiologic perspective -- 33. Bone-tageted treatment in CRPC management -- 34. Skeletal complications in CRPC patients -- 35. Urological complications in men dying from prostate cancer -- 36. Prediction of optimal docetaxel regimen for patients with mCRPC -- 37. Intermittent chemotherapy with decetaxel for mCRPC -- 38. Chemotherapy with cabazitaxel for ｍCRPC in Japanese men -- 39. New tageted approach to CRPC -- 40. Molecular basis of neuroendocrine prostate cancer -- 41. Gene therapy for prostate cancer -- 42. Immune therapy for CRPC -- 43. New approach to CRPC using inactivated virus -- 44. Patient-reported outcome in the management of CRPC.
520			_aThis comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.
650		7	_2embne _9182337 _aPróstata _xCáncer
700	1		_aArai, Yoichi _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aOgawa, Osamu _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n2018188955
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _9106996
776	0	8	_iPrinted edition: _z9789811070129
776	0	8	_iPrinted edition: _z9789811070143
776	0	8	_iPrinted edition: _z9789811339066
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-10-7013-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0